65,437 trials
Cardiomyopathy, Hypertrophic
Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506
Lung Cancer
Primary: Completion of Tele-Navi LCS — 20 Participants
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
Obesity
Primary: Weight — -2.08; -3.42; -4.36; -2.4 lbs
Inflammatory Bowel Diseases
Primary: Number of Participants With Acute Infusion Reaction as Assessed by the Nursing Staff of the Infusion Unit — 27; 30; 0; 0 Participants
Diabetes Mellitus
Primary: Change in Hemoglobin A1c — -0.37; -0.15; -0.31; -0.20 percentage of glycated hemoglobin
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Kidney Disease, Chronic
Primary: Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients…
Chemotherapy-induced Neutropenia
Primary: Duration of Severe Neutropenia (DSN) — 0.246; 0.770 Days
Urinary Incontinence,Stress · Urinary Incontinence
Primary: Number of Participants With Negative Urinary Stress Test (no Leakage Noted on Examination During Cough or Valsalva Maneuvers at a Standardized Bladder Volume of 300 mL)…
Infant of Diabetic Mother · Oxidative Stress · Vagus Nerve Stimulation
Primary: Daily Oral Feeding Volumes : Difference in Mean Increase — 2.1 ml/kg/day po daily change — p=0.009
Health Personnel · Stress · Anxiety
Primary: Change in Perceived Stress Scale (PSS) — -7.8; -1.2 score on a scale
Binge Drinking
Primary: Sympathetic Nerve Activity Burst Frequency — 18; 20 Burst/Min — p=0.283
Stage III Fallopian Tube Cancer AJCC v7 · Stage III Ovarian Cancer AJCC v6 and v7 · Stage III Primary Peritoneal Cancer AJCC v7
Primary: To Evaluate Progression-free Survival of Paclitaxel/Carboplatin and Pembrolizumab in Patients With Advanced Stage, Metastatic Ovarian Cancer Undergoing NACT — 14.2 months
Attention Deficit Hyperactivity Disorder
Primary: DAT Availability — 2.68; 2.85 ratio